FDA Could Soon Limit Use of Only Drug for COVID Prevention
Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.
Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial | Invivyd
PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in Exploratory Analysis Ongoing Phase 3 Clinical Trial May be useful for PRE-EXPOSURE PROPHYLAXIS (Prep) in immunocompromised & immunocompetent
